Precision Medicine Group secures major investment from Blackstone

Bethesda-based Precision Medicine Group (PMG) and Blackstone (NYSE: BX) Friday announced that PMG, a provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone. Terms of the transaction were not disclosed. The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *